57 results
Page 2 of 3
6-K
EX-99
icfkpix4g7h9h4mrq
3 Jun 20
Current report (foreign)
8:30am
424B5
1vgktbvwh bj
28 May 20
Prospectus supplement for primary offering
12:00pm
6-K
EX-99
f7v095ba
28 May 20
Current report (foreign)
11:56am
424B5
jj79q8j
5 Feb 19
Prospectus supplement for primary offering
5:12pm
424B5
20oy jrrpfsow00qwck
4 Feb 19
Prospectus supplement for primary offering
5:52pm
F-3
6k8emnez gjhrm9
26 Dec 18
Shelf registration (foreign)
4:11pm
6-K
EX-10.2
j1dqrliny9q7zkg
3 Oct 18
BioLineRx Increases Stake in BL-8040, its Lead Oncology
6:03am
20-F/A
EX-4.33
d8awj5rc5k 4mwfqwx
31 May 16
Annual report (foreign) (amended)
12:00am
F-3/A
h2mx4kg3zyrek
16 Oct 15
Shelf registration (foreign) (amended)
12:00am
424B5
5kxswgcy3p3wuepc1
6 Mar 15
Prospectus supplement for primary offering
12:00am
424B5
assxgnp6
5 Mar 15
Prospectus supplement for primary offering
12:00am
424B2
xr4404uuh
13 Jun 14
Prospectus for primary offering
12:00am
F-3
8kjpcq2nnuus7
30 May 14
Shelf registration (foreign)
12:00am
424B5
7pu2 5clvs2zxj6dy
4 Mar 14
Prospectus supplement for primary offering
12:00am
424B5
dp0guxiz
3 Mar 14
Prospectus supplement for primary offering
12:00am
424B3
9zete am594
8 Aug 13
Prospectus supplement
12:00am
424B5
arviu7ycrym9 ov
17 May 13
Prospectus supplement for primary offering
12:00am
424B5
hu4gkdg1 ry8rwei4sm
17 May 13
Prospectus supplement for primary offering
12:00am
6-K
EX-10.1
u9qw8cvh
17 May 13
BioLineRx Enters into “At-The-Market” Offering
12:00am